Considering that the studies investigating tankyrase inhibitors in CRC have been conducted on a very limited number of CRC cell lines and explants, we set out to determine the efficacy of a novel tankyrase inhibitor (AZ1366) [17] as a single agent and in combination with irinotecan in 18 unique CRC PDTX models. Here, TNKS is linked to colorectal carcinoma.